Phaeohyphomycosis in China.

He, Yun; Zheng, Hai-Lin; Mei, Huan; Lv, Gui-Xia; Liu, Wei-da; Li, Xiao-Fang

He, Yun; Zheng, Hai-Lin; Mei, Huan; Lv, Gui-Xia; Liu, Wei-da; Li, Xiao-Fang.

Afiliação

He Y; Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, China.
Zheng HL; Institute of Dermatology, Chinese Academy of Medical Science, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.
Mei H; Skin Disease Prevention and Treatment Institute of Yixing, Yixing, China.
Lv GX; Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, China.
Liu WD; Institute of Dermatology, Chinese Academy of Medical Science, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.
Li XF; Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, China.

Front Cell Infect Microbiol ; 12: 895329, 2022.

Article em En | MEDLINE | ID: mdl-35770068

Assuntos

COVID-19; Feoifomicose; Antifúngicos/uso terapêutico; Fungos; Humanos; Feoifomicose/diagnóstico; Feoifomicose/tratamento farmacológico; Feoifomicose/epidemiologia; Qualidade de Vida; Voriconazol

Palavras-chave

clinical features; diagnosis; drug sensitive; epidemiology; melanized fungi; phaeohyphomycosis; risk factors; treatment strategy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feoifomicose / COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: Front Cell Infect Microbiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google